These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 25808463

  • 1. Anti-angiogenic activity of thienopyridine derivative LCB03-0110 by targeting VEGFR-2 and JAK/STAT3 Signalling.
    Kim BH, Lee Y, Yoo H, Cui M, Lee S, Kim SY, Cho JU, Lee H, Yang BS, Kwon YG, Choi S, Kim TY.
    Exp Dermatol; 2015 Jul; 24(7):503-9. PubMed ID: 25808463
    [Abstract] [Full Text] [Related]

  • 2. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW, Lien JC, Kuo SC, Huang TF.
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [Abstract] [Full Text] [Related]

  • 3. Isogambogenic acid inhibits tumour angiogenesis by suppressing Rho GTPases and vascular endothelial growth factor receptor 2 signalling pathway.
    Fan Y, Peng A, He S, Shao X, Nie C, Chen L.
    J Chemother; 2013 Oct; 25(5):298-308. PubMed ID: 24070138
    [Abstract] [Full Text] [Related]

  • 4. Indirubin inhibits tumor growth by antitumor angiogenesis via blocking VEGFR2-mediated JAK/STAT3 signaling in endothelial cell.
    Zhang X, Song Y, Wu Y, Dong Y, Lai L, Zhang J, Lu B, Dai F, He L, Liu M, Yi Z.
    Int J Cancer; 2011 Nov 15; 129(10):2502-11. PubMed ID: 21207415
    [Abstract] [Full Text] [Related]

  • 5. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
    Hong SW, Jung KH, Park BH, Zheng HM, Lee HS, Choi MJ, Yun JI, Kang NS, Lee J, Hong SS.
    Cancer Lett; 2013 May 10; 332(1):74-82. PubMed ID: 23348694
    [Abstract] [Full Text] [Related]

  • 6. A novel 2-aminobenzimidazole-based compound Jzu 17 exhibits anti-angiogenesis effects by targeting VEGFR-2 signalling.
    Lien JC, Chung CL, Huang TF, Chang TC, Chen KC, Gao GY, Hsu MJ, Huang SW.
    Br J Pharmacol; 2019 Oct 10; 176(20):4034-4049. PubMed ID: 31368127
    [Abstract] [Full Text] [Related]

  • 7. Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling.
    Zhou X, Yue GG, Liu M, Zuo Z, Lee JK, Li M, Tsui SK, Fung KP, Sun H, Pu J, Lau CB.
    Oncotarget; 2016 Dec 13; 7(50):82820-82835. PubMed ID: 27756875
    [Abstract] [Full Text] [Related]

  • 8. Cucurbitacin E, a tetracyclic triterpenes compound from Chinese medicine, inhibits tumor angiogenesis through VEGFR2-mediated Jak2-STAT3 signaling pathway.
    Dong Y, Lu B, Zhang X, Zhang J, Lai L, Li D, Wu Y, Song Y, Luo J, Pang X, Yi Z, Liu M.
    Carcinogenesis; 2010 Dec 13; 31(12):2097-104. PubMed ID: 20732905
    [Abstract] [Full Text] [Related]

  • 9. 12-Deoxyphorbol 13-palmitate inhibit VEGF-induced angiogenesis via suppression of VEGFR-2-signaling pathway.
    Xu HY, Pan YM, Chen ZW, Lin Y, Wang LH, Chen YH, Jie TT, Lu YY, Liu JC.
    J Ethnopharmacol; 2013 Apr 19; 146(3):724-33. PubMed ID: 23434607
    [Abstract] [Full Text] [Related]

  • 10. Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2.
    Borzilleri RM, Bhide RS, Barrish JC, D'Arienzo CJ, Derbin GM, Fargnoli J, Hunt JT, Jeyaseelan R, Kamath A, Kukral DW, Marathe P, Mortillo S, Qian L, Tokarski JS, Wautlet BS, Zheng X, Lombardo LJ.
    J Med Chem; 2006 Jun 29; 49(13):3766-9. PubMed ID: 16789733
    [Abstract] [Full Text] [Related]

  • 11. A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo.
    LaMontagne KR, Butler J, Borowski VB, Fuentes-Pesquera AR, Blevitt JM, Huang S, Li R, Connolly PJ, Greenberger LM.
    Angiogenesis; 2009 Jun 29; 12(3):287-96. PubMed ID: 19544081
    [Abstract] [Full Text] [Related]

  • 12. Salinomycin exerts anti-angiogenic and anti-tumorigenic activities by inhibiting vascular endothelial growth factor receptor 2-mediated angiogenesis.
    Li T, Liu X, Shen Q, Yang W, Huo Z, Liu Q, Jiao H, Chen J.
    Oncotarget; 2016 May 03; 7(18):26580-92. PubMed ID: 27058891
    [Abstract] [Full Text] [Related]

  • 13. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
    Li X, Wang X, Ye H, Peng A, Chen L.
    Cancer Chemother Pharmacol; 2012 Sep 03; 70(3):425-37. PubMed ID: 22814678
    [Abstract] [Full Text] [Related]

  • 14. Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.
    Glaser KB, Li J, Marcotte PA, Magoc TJ, Guo J, Reuter DR, Tapang P, Wei RQ, Pease LJ, Bui MH, Chen Z, Frey RR, Johnson EF, Osterling DJ, Olson AM, Bouska JJ, Luo Y, Curtin ML, Donawho CK, Michaelides MR, Tse C, Davidsen SK, Albert DH.
    J Pharmacol Exp Ther; 2012 Dec 03; 343(3):617-27. PubMed ID: 22935731
    [Abstract] [Full Text] [Related]

  • 15. ZLM-7 exhibits anti-angiogenic effects via impaired endothelial cell function and blockade of VEGF/VEGFR-2 signaling.
    Su M, Huang J, Li J, Qin X, Tang X, Jin F, Chen S, Jiang C, Zou Z, Peng K, Nuruzzaman M, Zhang J, Luo J, Liu S, Luo Z.
    Oncotarget; 2016 Apr 05; 7(14):19018-30. PubMed ID: 26967559
    [Abstract] [Full Text] [Related]

  • 16. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
    Wang D, Tang F, Wang S, Jiang Z, Zhang L.
    Cancer Chemother Pharmacol; 2012 Jan 05; 69(1):173-83. PubMed ID: 21638122
    [Abstract] [Full Text] [Related]

  • 17. Hispidulin, a small flavonoid molecule, suppresses the angiogenesis and growth of human pancreatic cancer by targeting vascular endothelial growth factor receptor 2-mediated PI3K/Akt/mTOR signaling pathway.
    He L, Wu Y, Lin L, Wang J, Wu Y, Chen Y, Yi Z, Liu M, Pang X.
    Cancer Sci; 2011 Jan 05; 102(1):219-25. PubMed ID: 21087351
    [Abstract] [Full Text] [Related]

  • 18. 1-o-acetylbritannilactone (ABL) inhibits angiogenesis and lung cancer cell growth through regulating VEGF-Src-FAK signaling.
    Zhengfu H, Hu Z, Huiwen M, Zhijun L, Jiaojie Z, Xiaoyi Y, Xiujun C.
    Biochem Biophys Res Commun; 2015 Aug 21; 464(2):422-7. PubMed ID: 26102035
    [Abstract] [Full Text] [Related]

  • 19. Arenobufagin, a bufadienolide compound from toad venom, inhibits VEGF-mediated angiogenesis through suppression of VEGFR-2 signaling pathway.
    Li M, Wu S, Liu Z, Zhang W, Xu J, Wang Y, Liu J, Zhang D, Tian H, Li Y, Ye W.
    Biochem Pharmacol; 2012 May 01; 83(9):1251-60. PubMed ID: 22305746
    [Abstract] [Full Text] [Related]

  • 20. Capsiate, a nonpungent capsaicin-like compound, inhibits angiogenesis and vascular permeability via a direct inhibition of Src kinase activity.
    Pyun BJ, Choi S, Lee Y, Kim TW, Min JK, Kim Y, Kim BD, Kim JH, Kim TY, Kim YM, Kwon YG.
    Cancer Res; 2008 Jan 01; 68(1):227-35. PubMed ID: 18172315
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.